CHINA: RED MOON RISING - Franklin Templeton

Page created by Marshall Sherman
 
CONTINUE READING
CHINA: RED MOON RISING - Franklin Templeton
Perspective from
Franklin Templeton
Investment Solutions

CHINA: RED MOON RISING
August 2021            KEY POINTS
                       • China’s “firsts” drove early equity outperformance in 2020, but has given way to marked
                         underperformance in 2021, trailing global peers by 26% year to date (YTD).1

                       • Regulatory recapture and macro headwinds dominate the landscape in China—a renewed
                         regulatory push toward common prosperity, the re-emergence of COVID and limited
                         monetary and fiscal policy support—and are not expected to subside anytime soon.

                       • COVID’s comeback can’t be ignored as China begins to implement many heavy-handed
                         policies again to control the spread.

                       • Portfolio positioning will likely remain unchanged in terms of our less-favorable view on
                         Chinese equities this year. However, our view has slightly improved given the recent
                         sell-off and marked deterioration in sentiment.

                       THE TORTOISE VS. THE HARE IN THE YEAR OF THE OX
                       The classic tale of speed vs. perseverance has played out before us in global equity markets
                       since 2020. Early in the pandemic, China emerged as the hare, swiftly outperforming other
                       global equity markets through 2020 due to strong control over the COVID-19 outbreak,
                       quick monetary and fiscal policy accommodation, and resilient export growth. China initially
                       seemed destined to be this cycle’s “winner”—but not so fast.

                       While other global equities were initially paced as the tortoise, their slow and steady
                       approach has been paying off since the March 2020 low, with only two drawdowns of ~7%
                       since then.2 Now in 2021, global equities continued to rise, gaining 14% YTD,3 while the
                       Chinese equity markets have run out of steam and experienced a drawdown of more than
                       30% since February 2021, and are currently underperforming global equities by 26% YTD.4
CHINA: RED MOON RISING - Franklin Templeton
CHINESE EQUITIES:        Index rebased to 100 on January 2020
FROM LEADER TO LAGGARD   160
January 1, 2020–
                         150
August 17, 2021
                         140

                         130

                         120

                         110

                         100

                          90

                          80

                          70
                          60
                               Jan Feb     Mar      Apr   May   Jun   Jul   Aug   Sep     Oct    Nov   Dec       Jan Feb Mar    Apr    May    Jun   Jul       Aug
                               2020                                                                              2021
                               MSCI USA Net Total          MSCI China Net Total         MSCI World ex USA Net         MSCI Emerging Markets ex China
                               Return USD Index            Return USD Index             Total Return USD Index        Net Return USD Index
                         For illustrative purposes only and not reflective of the performance or portfolio composition of any Franklin Templeton fund.
                         Sources: Bloomberg, Macrobond. Indexes are unmanaged and one cannot directly invest in them. They do not include fees, expenses
                         or sales charges. Past performance is not an indicator or a guarantee of future results. Important data provider notices and terms
                         available at: www.franklintempletondatasources.com.

                         CHINA’S “FIRSTS”
                         China’s early pandemic outperformance was based on the ability to execute effectively on
                         many global “Firsts”:

                         • China was the first nation to endure the COVID-19 crisis, with the initial outbreak
                           emanating in Wuhan before spreading throughout the world.
                         • China was one of the first nations to execute (and then emerge from) the COVID-19
                           lockdowns, perform contact tracing, and require public adherence to mask-wearing.
                         • China was a premier beneficiary from rising global goods demand, where its export
                           industry surged in response to higher demand for supplies including medical equipment
                           and housing- related goods.

                         China’s transition from leader to laggard was also due to another “first,” as China was the
                         first major nation to incrementally tighten its monetary policy stance following the
                         COVID-19 crisis. For instance, China’s credit growth had begun to decline as early as
                         January 2021.

                         A newfound sense of economic stability would eventually allow policymakers to resume the
                         battle on economic leverage, an issue that had eluded policymakers over the past
                         decade. For perspective, China’s nonfinancial private sector credit had more than doubled
                         from the great financial crisis in 2008, rising from 112% of global domestic product
                         (GDP) to 222%.5 During this same period, the debt levels of most advanced economies
                         merely trended sideways. Overnight lending rates climbed to their highest rate in six years
                         in January 2021.6

2                        China: Red moon rising
CHINA: RED MOON RISING - Franklin Templeton
CHINA’S CREDIT BOOM              Nonfinancial credit (% of gross domestic product)
January 1, 2002–                 230%
October 1, 2020                    220
                                   210
                                   200
                                   190
                                   180
                                   170
                                   160
                                   150
                                   140
                                   130
                                   120
                                   110
                                     Jan-02            Feb-04     Mar-06        Apr-08        May-10          Jun-12     Jul-14       Aug-16        Sep-18      Oct-20
                                      China            Advanced economies
                                 Sources: BIS, Macrobond.

                                 CHINA’S REGULATORY RECAPTURE
                                 Tightening monetary policy was the first shoe to drop in 2021, but not the last. As the year
                                 progressed, a barrage of regulatory surprises stifled markets as Chinese policymakers
                                 turned their attention toward their goal of “common prosperity for all.” Regulators started
                                 zeroing in on giant technology platform companies, and most recently have turned to
 China’s tech giants:
                                 the private education sector as the cost of private tuition has become a burden for most of
 Quick facts7
 • Alibaba hosts twice as        the parents.
   much e-commerce activity
   as Amazon                     Many of these regulatory initiatives are unlikely to end soon since they fulfill a part of
 • Tencent has 1.2 billion       China’s Communist Party (CCP) long-term strategic vision. The CCP has been putting
   users and is the world’s      together five-year socioeconomic plans since 1953 and are now on its 14th five-year plan
   most popular app              targeting years 2021–2025. The most recent 50 regulatory actions range from antitrust to
 • China has 160 Unicorns        data violations and green development—analogous to environmental, social and governance
   (half are in fields such
                                 (ESG) efforts in Western economies.
   as artificial intelligence,
   big data, robotics)
                                 We do not think China will significantly curtail efforts to increase productivity, especially as
 • Didi, which provides
   transports, has more users
                                 demographic headwinds are likely to pick-up in the upcoming decade. However, China is
   than the United States        outcome-oriented and is prioritizing “common prosperity for all”; regulatory intervention will
   has people                    likely remain a key tool to achieve this outcome, and even increased market volatility is
                                 unlikely to change this approach.

CHINA’S ROADMAP TO
A “COMMON PROSPERITY”

                                 Environmental goals                           Social goals                                Governance goals

                                 Decarbonization                               Rebalance economy toward labor              Reduce data security risks
                                 Peak emissions by 2030, carbon neutrality     Lower costs of housing, health care and     Enhance cybersecurity capabilities
                                 by 2060                                       education
                                                                                                                           Enhance economic self-sufficiency
                                                                               Provide retirement vehicles similar to
                                                                               social security

3                                China: Red moon rising
COVID’S COMEBACK
                             On top of a new regulatory reset, China is now dealing with a COVID-19 resurgence as the
                             Delta variant has permeated through the country. After the initial outbreak, China’s
                             defense against COVID-19 was laudable, as strict lockdowns and contact tracing initiatives
                             allowed the country to quell the number of cases and ultimately emerge as the first
                             nation to begin normalizing its economy.

                             Unfortunately, the Delta variant is estimated to be more than twice as contagious as
                             previous strains,8 making it much more difficult to prevent the transmission using lock-
                             downs. Full vaccination is viewed as the best protection against Delta, and here, China is on
                             par with developed market peers—China’s vaccination rate is estimated to be ~55%
                             of their population, according to China’s National Health Commission.9 This compares to
                            ~50% and ~60% (fully vaccinated) for the United States and eurozone, respectively.10
                             China’s remaining challenge lies not only in vaccinating the remainder of their population,
                             around 630 million people, but also in coordinating this effort given the massive
                             geographic reach of its territory. Moreover, the efficacy of their two most common vaccines,
                             Sinovac and Sinopharm, has come under question as some studies have suggested
                             that they are less protective than Western vaccine rivals, such as Pfizer and Moderna.11

                             China has already begun to undertake draconian measures in response to the Delta
                             outbreak, enacting lockdowns in over 30 cities where clusters had emerged.12 This policy
                             response contrasts with many other nations that are refraining from lockdowns and is
                             likely to have a substantial effect on economic growth if sustained for any period of time.

                             MULTI-ASSET PERSPECTIVE
                             The macro environment in China presents several headwinds, which have clearly buffeted
                             Chinese equities this year. The question we ask ourselves: is the bad news already
                             priced in? Clearly, some of the news has been priced in as Chinese equities have de-rated,
                             both in absolute terms and relative to their global peers. Of interest to us at FTIS is
                             that some sentiment indicators appear to be near all-time pessimistic levels. This usually
                             serves as a good contrarian indicator. As Sir John Templeton used to say, “Bull markets
                             are born on pessimism, grow on skepticism, mature on optimism and die on euphoria.”

CHINESE MARKETS HAVE         Price-to-book ratio (log scale)
DE-RATED                      4
June 1, 2012–July 1, 2021

                              2

                              1
                             Jan-12                 Aug-13                 Mar-15                Oct-16                   May-18               Dec-19                  Jul-21
                                  China, Equity indices, MSCI, IMI (Large, mid & small cap), Index, price/book value
                                  AC World, Equity indices, MSCI, IMI (Large, mid & small cap), Index, price/book value
                             Price-to-book ratio measures the current price of an index relative to the book value of the same index. It is a measure of valuation, where a
                             higher price-to-book ratio signifies a higher valuation.
                             Sources: FactSet, MSCI, Macrobond. Indexes are unmanaged and one cannot directly invest in them. They do not include fees, expenes or
                             sales charges. Past performance is not an indicator or a guarantee of future results.

4                            China: Red moon rising
As we weigh these considerations, the macro headwinds keep us cautious in regard to
                                            Chinese equities, although we think it is reasonable to rethink our views given the recent
                                            pullback in Chinese equities and sentiment. We are monitoring fiscal policymakers
                                            for additional easing measures that could lead us to evolve our positioning and outlook.

                                            CONTRIBUTORS

                                            Gene Podkaminer, CFA                         Miles Sampson, CFA                          Michael Kerwin, CFA
                                            Head of Research                             Senior Research Analyst                     Senior Research Analyst

                                            Wylie Tollette, CFA                              Nick Hooten, CFA                                 Subash Pillai
                                            Head of Client Investment                        Regional Head of Client                          Regional Head of Client
                                            Solutions                                        Investment Solutions—Americas                    Investment Solutions—APAC

                                            Peter Vincent                                    Kent Shepherd                                    Josh Greco
                                            Regional Head of Client                          Senior Institutional Portfolio                   Head of Institutional Portfolio
                                            Investment Solutions—EMEA                        Manager—Multi-Asset Income                       Management
                                                                                             Strategies

Endnotes
1. Source: MSCI China Net TR USD Index relative to MSCI ACWI Net TR USD, as of July 31, 2021. Indexes are unmanaged and one cannot directly invest in them. They do not include fees,
    expenses or sales charges. Past performance is not an indicator or a guarantee of future results.
2. Source: Macrobond; MCSI Total Return USD Index. March 2020 through August 17, 2021. MSCI makes no warranties and shall have no liability with respect to any MSCI data
    reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Indexes are unmanaged and one cannot directly invest in them.
    They do not include fees, expenses or sales charges. Past performance is not an indicator or a guarantee of future results.
3. Source: MSCI ACWI Total Net Return USD. Year-to-date return through August 17, 2021.
4. Source: Macrobond; MCSI China Net Total Return USD Index February 2021 through August 17, 2021. MSCI makes no warranties and shall have no liability with respect to any MSCI
    data reproduced herein. No further redistribution or use is permitted. This report is not prepared or endorsed by MSCI. Indexes are unmanaged and one cannot directly invest in them.
    They do not include fees, expenses or sales charges. Past performance is not an indicator or a guarantee of future results.
5. Sources: Macrobond, BIS as of July 31, 2021.
6. Source: Reuters, “China short-term rate hits near 6-year high on holiday demand, policy tightening worries. Reuters,” January 26, 2021.
7. Source: The Economist, “Xi Jinping’s assault on tech will change China’s trajectory,” August 14, 2021.
8. Source: US Centers for Disease Control and Prevention, “Delta Variant: What We Know about the Science,” August 19, 2021.
9. Source: Agencia EFE, China has fully vaccinated 55% of population: government, August 13, 2021.
10. Sources: USA Facts, US Coronavirus vaccine tracker, as of August 16, 2021. European Centre for Disease Prevention, COVID-19 Tracker, as of August 18, 2021.
11. Sources: The New England Journal of Medicine, “Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile, July 7, 2021. BBC News, “2021 and Covid: What do we know about
    China’s coronavirus vaccines?” July 13, 2021.
12. Source: The Washington Post, “New restrictions sweep China as officials race to contain delta outbreak,” August 3, 2021.

5                                           China: Red moon rising
IMPORTANT LEGAL INFORMATION
This material is intended to be of general interest only and should not be construed as individual investment advice or a recommen-
dation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice.
This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.
The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication
date and may change without notice. The underlying assumptions and these views are subject to change based on market and other
conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not
intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any
prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized.
The value of investments and the income from them can go down as well as up and you may not get back the full amount that you
invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks,
including possible loss of principal.
Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be
acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the
preparation of this material and Franklin Templeton (“FT”) has not independently verified, validated or audited such data. Although
information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its
accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The
mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any
securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an
investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the
comments, opinions and analyses in the material is at the sole discretion of the user.
Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates
and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton
institutional contact for further information on availability of products and services in your jurisdiction.
Issued in the U.S. by Franklin Distributors, LLC, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-
5236, franklintempleton.com - Franklin Distributors, LLC, member FINRA/SIPC, is the principal distributor of Franklin Templeton
U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in
jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.

Australia: Issued by Franklin Templeton Investments Australia Limited (ABN 87 006 972 247) (Australian Financial Services License Holder No. 225328), Level 19, 101 Collins Street,
Melbourne, Victoria, 3000. Austria/Germany: Issued by Franklin Templeton International Services S.à r.l., Niederlassung Deutschland, Frankfurt, Mainzer Landstr. 16, 60325 Frankfurt/
Main. Tel: 08 00/0 73 80 01 (Germany), 08 00/29 59 11 (Austria), Fax: +49(0)69/2 72 23-120, info@franklintempleton.de, info@franklintempleton.at. Canada: Issued by Franklin
Templeton Investments Corp., 200 King Street West, Suite 1500 Toronto, ON, M5H3T4, Fax: (416) 364-1163, (800) 387-0830, www.franklintempleton.ca. Netherlands: Franklin Templeton
International Services S.à r.l., Dutch Branch, World Trade Center Amsterdam, H-Toren, 5e verdieping, Zuidplein 36, 1077 XV Amsterdam, Netherlands. Tel: +31 (0) 20 575 2890. United
Arab Emirates: Issued by Franklin Templeton Investments (ME) Limited, authorized and regulated by the Dubai Financial Services Authority. Dubai office: Franklin Templeton, The Gate,
East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E. Tel: +9714-4284100 Fax: +9714-4284140. France: Issued by Franklin Templeton International
Services S.à r.l., French branch, 55 avenue Hoche, 75008 Paris France. Hong Kong: Issued by Franklin Templeton Investments (Asia) Limited, 17/F, Chater House, 8 Connaught Road
Central, Hong Kong. Italy: Issued by Franklin Templeton International Services S.à r.l.—Italian Branch, Corso Italia, 1 – Milan, 20122, Italy. Japan: Issued by Franklin Templeton
Investments Japan Limited. Korea: Issued by Franklin Templeton Investment Trust Management Co., Ltd., 3rd fl., CCMM Building, 12 Youido-Dong, Youngdungpo-Gu, Seoul, Korea 150-968.
Luxembourg/Benelux: Issued by Franklin Templeton International Services S.à r.l.—Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette,
L-1246 Luxembourg. Tel: +352-46 66 67-1 Fax: +352-46 66 76. Malaysia: Issued by Franklin Templeton Asset Management (Malaysia) Sdn. Bhd. & Franklin Templeton GSC Asset
Management Sdn. Bhd. This document has not been reviewed by Securities Commission Malaysia. Poland: Issued by Templeton Asset Management (Poland) TFI S.A.; Rondo ONZ 1; 00-124.
Warsaw. Romania: Franklin Templeton International Services S.à r.l. Luxembourg, Bucharest Branch, at 78-80 Buzesti Str, Premium Point, 8th Floor, Bucharest 1, 011017, Romania.
Registered with Romania Financial Supervisory Authority under no. PJM07.1AFIASMDLUX0037/10 March 2016 and authorized and regulated in Luxembourg by Commission de Surveillance
du Secteur Financier. Tel: + 40 21 200 9600. Singapore: Issued by Templeton Asset Management Ltd. Registration No. (UEN) 199205211E and Legg Mason Asset Management Singapore
Pte. Limited, Registration Number (UEN) 200007942R. Legg Mason Asset Management Singapore Pte. Limited is an indirect wholly owned subsidiary of Franklin Resources, Inc. 7 Temasek
Boulevard, #38-03 Suntec Tower One, 038987, Singapore. Spain: Issued by Franklin Templeton International Services S.à r.l.—Spanish Branch, Professional of the Financial Sector under
the Supervision of CNMV, José Ortega y Gasset 29, Madrid, Spain. Tel: +34 91 426 3600, Fax: +34 91 577 1857. South Africa: Issued by Franklin Templeton Investments SA (PTY) Ltd,
which is an authorised Financial Services Provider. Tel: +27 (21) 831 7400 Fax: +27 (21) 831 7422. Switzerland: Issued by Franklin Templeton Switzerland Ltd, Stockerstrasse 38,
CH-8002 Zurich. UK: Issued by Franklin Templeton Investment Management Limited (FTIML), registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL. Tel: +44 (0)20 7073
8500. Authorized and regulated in the United Kingdom by the Financial Conduct Authority. Nordic regions: Issued by Franklin Templeton International Services S.à r.l. Swedish Branch,
filial, Nybrokajen 5, SE-111 48, Stockholm, Sweden. Tel: +46 (0)8 545 012 30, nordicinfo@franklintempleton.com, authorised in Luxembourg by the Commission de Surveillance du Secteur
Financier to conduct certain financial activities in Denmark, Sweden, Norway, Iceland and Finland. Franklin Templeton International Services S.à r.l., Swedish Branch, filial conducts activi-
ties under supervision of Finansinspektionen in Sweden. Offshore Americas: In the U.S., this publication is made available only to financial intermediaries by Franklin Distributors, LLC,
member FINRA/SIPC, 100 Fountain Parkway, St. Petersburg, Florida 33716. Tel: (800) 239-3894 (USA Toll-Free), (877) 389-0076 (Canada Toll-Free), and Fax: (727) 299-8736. Investments
are not FDIC insured; may lose value; and are not bank guaranteed. Distribution outside the U.S. may be made by Franklin Templeton International Services, S.à r.l. (FTIS) or other sub-dis-
tributors, intermediaries, dealers or professional investors that have been engaged by FTIS to distribute shares of Franklin Templeton funds in certain jurisdictions. This is not an offer to
sell or a solicitation of an offer to purchase securities in any jurisdiction where it would be illegal to do so.
Please visit www.franklinresources.com to be directed to your local Franklin Templeton website.
CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

© 2021 Franklin Templeton. All rights reserved.                                                                                                                                         0821
You can also read